

Vylex Full Prescribing Info

Contents

Undenatured Type II Collagen (UC-II) 40mg, *Boswellia serrata* Gum Extract (Aflapin) 100mg

Description

Vylex contains UC-II, a novel undenatured type II collagen & Aflapin, a novel *Boswellia serrata* gum extract standardized to 20% AKBA. UC-II & Aflapin are patented active ingredients & support joint health by their disease-modifying anti-inflammatory & cartilage protecting pathways. Research in multiple clinical trials have shown safety & efficacy in reducing joint pain (from 5-7 days), stiffness & increasing physical function & mobility.

Action

These disease-modifying mechanism of action have been evaluated through multiple pre-clinical studies.

- i) Activates T regulatory (Treg) cells which increase the production of anti-inflammatory mediators such as IL-4, IL-10 & TGF- β , which in turn, stimulate chondrocytes to synthesize cartilage matrix components.
- ii) Inhibits production of cartilage degrading enzymes, matrix metalloproteinases MMP-3 & MMP-13, which prevents cartilage breakdown.
- iii) Reduce the production of pro-inflammatory mediators such as 5-lipoxygenase, IL-1 β , TNF- α , IL-2 & IL-17

Indications/Uses

Adjunctive therapy for OA.

Dosage/Direction of Use

1 capsule daily for 3-6 months.

Overdosage

There is no experience with clinically significant over dosage. Toxicological studies indicate that there is no significant acute & sub-chronic toxic effect (oral LD₅₀ of more than 5000mg/kg in animal) & it has a broad spectrum safety profile. However, in case of accidental over dosage, symptomatic treatment should be employed under guidance of a physician.

Contraindications

Hypersensitivity to the active substances or to any of the excipients such as collagen & *Boswellia serrata*.

Special Precautions

No known special precautions

Use In Pregnancy & Lactation

Insufficient information currently, not recommended for pregnancy & lactation.

Adverse Reactions/Side Effects

Safety & tolerability have been shown in multiple clinical trials on patients with OA. There were no significant changes in hematologic, biochemical, vital signs & urinary parameters. Minor adverse events reported were headache & GI-related which were similar to the placebo group & not due to the medicine.

Drug Interactions

No known interaction with other drugs

Storage

Store below 30°C away from sunlight & moisture

MIMS Class

Other Drugs Acting on Musculo-Skeletal System

ATC Classification

M01AX - Other antiinflammatory and antirheumatic agents, non-steroids; Used in the treatment of inflammation and rheumatism.

Regulatory Classification

NP

Presentation/Packing**Form**

Vylex cap (vegecap) 280mg

Packing

30's

